Effects of Hypothyroidism Treatment on the Level of Vascular Endothelial Growth Factor

O.M. Didushko

Abstract


The objective of the investigation is identifying the level of vascular endothelial growth factor in patients with primary hypothyroidism and influence of complex treatment on its levels. Materials and methods. One hundred and thirty three patients with primary hypothyroidism were examined. All patients were grouped into group 1 containing 32 patients with hypothyroidism resulted from autoimmune thyroiditis (AIT) without obesity; group 2 involving 34 obese patients with autoimmune thyroiditis and hypothyroidism; group 3 including 34 patients with manifested hypothyroidism without obesity and Group 4, encompassing the rest 33 obese patients with post-operative hypothyroidism. Results. Patients’ data have shown significant increase of vascular endothelial growth factor levels in all groups, but the most expressed changes of vascular endothelial growth factor secretion have been noticed in obese patients with hypothyroidism resulting from autoimmune thyroidism. The possibility to increase the efficacy of treating such patients by means of complex use of LT4, enalapril and atorvastatin for six months has been discussed. Such complex use of LT4, enalapril and atorvastatin enhances the therapeutic effect of the background therapy and decreases the overproduction of vascular endothelial growth factor. Conclusions. With manifested hypothyroidism, levels of vascular endothelial growth factor in blood plasma are significantly higher in both obese and not obese patients. The highest indices have been found in obese patients with manifested hypothyroidism resulting from autoimmune thyroidism. Complex use of LT4, enalapril and atorvastatin for six months decreases vascular endothelial growth factor overproduction.


Keywords


hypothyroidism; vascular endothelial growth factor; levothyroxine; angiotensine transforming enzyme inhibitor; atorvastatin

References


Gavrilenko T.I., Ryizhkova N.A., Parhomenko A.N. Sosudistyi endotelialnyi faktor rosta v klinike vnutrennih zabolevaniy i ego patogeneticheskoe znachenie // Ukrayinskyi kardiologichnyi zhurnal. – 2011. – №4. – C. 87-95.

C.N. Koval, D.K. Miloslavskiy, I.A. Snegurskaya i dr. Terapevticheskiy angiogenez pri zabolevaniyah vnutrennih organov – vozmozhnosti i perspektivy // Visnyk problem biologiyi y meditsyny. — 2013. — № 4, Tom 1(104) — S. 20-27.

Lupinskaya Z.A., Zarifyan A.G., Gurovich T.Ts., Shleyfer S.G. Endoteliy. Funktsiya i disfunktsiya. — Bishkek: KRSU, 2008. — 373 c.

Orlova M.M., Rodionova T.I. Diagnosticheskaya znachimost issledovaniya syivorotochnoy kontsentratsii i mochevoy ekskretsii nekotoryih tsitokinov pri manifestnom gipotireoze // Tsitokinyi i vospalenie. – 2012. – №2 (11). – S. 24-28.

Seredyuk V.N. Efektyvnist ingibitoriv angiotenzinperetvoryuvalnogo fermentu i blokatoriv retseptoriv angiotenzynu-II u hvoryh iz hronichnym legenevym sertsem za dynamikoyu vaskuloendotelialnogo faktora rostu // Ukrayinskyi terapevtychnyi zhurnal.- 2010. – №4. – S. 67-71.

Asselbergs F.W., de Boer R.A., Diercks G.F. et al. Vascular endothelial growth factor: the link between cardiovascular risk factors and microalbuminuria? // Int. J. Cardiol. — 2004. — Vol. 93(2–3). — Р. 211-215.

Ayerden Ebinz F., Haksun E., Ulver D.B. et al. The relationship between vascular endothelial growth factor (VEGF) and microalbuminuria in patients with essential hypertension // Intern. Med. — 2008. — Vol.47, № 17. — Р.1511—1516.

Biselli P.M., Guerzoni A.R., de Godoy M.F. et al. Vascular endothelial growth factor genetic variability and coronary artery disease in Brazilian population // Heart Vessels. — 2008. — 23(6). — 371-5.

Hansen A.H., Nielsen J.J., Saltin B., Hellsten Y. Exercise training normalizes skeletal muscle vascular endothelial growth factor levels in patients with essential hypertension // J. Hypertens. — 2010. — 28(6). — Р. 1176-85.

Ferrara N. Vascular endothelial growth factor // Arterioscler. Thromb.Vasc. Biol. — 2009. — 29. — 789-791.

Siervo M., Ruggiero D., Sorice R. et al. Angiogenesis and biomarkers of cardiovascular risk in adults with metabolic syndrome // J. Intern. Med. — 2010. — 268(4). — 338-47.

Suzuki H., Murakami M., Shoji M. et al. Hepatocyte growth factor and vascular endothelial growth factor in ischemic heart disease // Coron. Artery Dis. — 2003. — 14. — 301-307.

Trape J.C., Morales R., Molina X. et al. Vascular endothelial growth factor serum concentrations in hypercholesterolemic patients // Scand. J. Clin. Lab. Invest. — 2006. — 663. — 261-267.

Wada H., Satoh N., Kitaoka S. et al. Soluble VEGF receptor-2 is increased in sera of subjects with metabolic syndrome in association with insulin resistance // Atherosclerosis. — 2010. — 208(2). — 512-7.

Zorenal K., Mys’liwska J., Mys’liwiec M. et al. Association between vascular endothelial growth factor and hypertension in children and adolescents type I diabetes mellitus // J. Hum. Hypert. — 2010. — Vol. 24. — Р. 755-762.




DOI: https://doi.org/10.22141/2224-0721.6.70.2015.72638

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru